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        To my family

ABSTRACT
         The estrogen receptor (ER) isoforms, ERα and ERβ, mediate the physiological 
functions of the female hormone estrogen. They share high degree of similarity 
but also show significant differences in many aspects, such as cell and tissue 
distribution. The activities of ER are tightly regulated by different factors at 
multiple levels. The biological action of estrogen is the result of a balance 
between ERα and ERβ activities; and disruption of this balance leads to various 
health disorders. Understanding the mechanisms of ER subtype specific regulation 
is critical to understand estrogen signaling in health and disease. In this thesis, we 
study the possible mechanisms by which estrogen signaling could be regulated in 
an ER subtype-specific manner.
     Intracellular ERα and ERβ protein levels or ERα/ERβ ratio are important 
determinants for estrogen action. Cellular regulatory factors could affect estrogen 
signaling by direct regulation of intracellular levels of individual ER isoforms. 
In paper I we demonstrate that the circadian system specifically modulates the 
expression of ERβ. We show that circadian regulators are recruited to the E-
box enhancer in ERβ promoter and regulate the transcription of ERβ. Thus, the 
intracellular level of ERβ as well as ERα/ERβ ratio vary significantly at different 
times of the day.
      Cellular factors could affect the transcription also by regulating ERs on the 
estrogen target gene promoter. In paper II, we show that the hepatitis B virus X 
protein associated protein 2 (XAP2) also known as ARA9 influences estrogen 
signaling by interacting with ERα on the promoter region of ER-target gene in 
breast cancer cells. Through this mechanism, XAP2 regulates the estrogen target 
gene transcription in an ER subtype-specific manner, as XAP2 inhibits ERα, but 
not ERβ-mediated transcription.
     In paper III we identify a novel epigenetic mechanism under the ER subtype-
specific regulation of gene expression. We show that ERβ, but not ERα, is essential 
in maintaining the unmethylated state of one specific CpG in glucose transporter 
4 (Glut4) promoter. This CpG is part of a specificity protein 1 (Sp1) binding 
site and this regulation is important for normal Sp1 recruitment and Glut4 
transcription in adipocytes.
      In conclusion, we have identified three novel pathways in mediating the ER 
subtype specific regulatory effects.
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1 INTRODUCTION
1.1 Hormones and hormone signaling
Hormones are chemical messengers produced and secreted by endocrine glands. 
They are released directly into the blood and coordinate the functions of different 
organs throughout the body. Hormone-regulated biological activities are crucial 
in maintenance of the physiological homeostasis and regulating physiological 
processes including growth and development, metabolism, electrolyte balances, 
and reproduction [1]. Based on their chemical structures, hormones can be 
divided into three classes: peptide hormones such as insulin and growth hormone, 
amino acid derivates such as tryptophan, as well as lipid-derived hormones such 
as steroid hormones.
Hormones initiate a biological response by binding to their specific receptors in 
the target cell. In the case of steroid hormones, the hormone can cross the cell 
membrane and bind to the intracellular receptor. This triggers a conformational 
change in the receptor and results in an activated transcription factor that 
mediates a cellular response. 
1.2 Estrogen receptors
The female sex hormone estrogen is one of the first isolated steroid hormones. Like 
other steroid hormones, estrogens exert their biological actions by binding to the 
specific intracellular receptors, namely estrogen receptors (ERs). ER-mediated 
estrogen signaling is essential for the normal female reproductive function 
by controlling the development of female secondary sexual characteristics, 
regulation of gonadotropin secretion for ovulation as well as preparation of tissues 
for progesterone response. However, the importance of estrogens for man and non-
reproductive processes has also been emphasized. For example, estrogens have 
been identified to play critical roles in maintenance of bone mass, regulation of 
lipid synthesis and the regulation of insulin responsiveness [2,3,4]. Disregulation 
of estrogen signaling may promote the pathological processes of various 
diseases, such as reproductive disorders [5], cancer [6,7], metabolic syndrome 
[8], behavioral disorder [9] and so on.
1.2.1 Nuclear receptor superfamily
ERs belong to the nuclear receptor (NR) superfamily, a family of ligand activated 
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transcription factors. A large number of nuclear hormone receptors have been 
identified, including steroid hormones receptors (e.g. ER, androgen receptor AR), 
thyroid hormone receptors (TRs), retinal acid receptors (RARs) and vitamin D 
receptors (VDRs), as well as different “orphan receptors” with unknown natural 
ligand (e.g. Liver X receptors LXRs, peroxisome proliferator-activated receptors 
PPARs) [10,11]. 
NRs are key players in diverse biological functions, including homeostasis, 
reproduction, development and metabolism. NR biological activities are often 
controlled by small compounds known as ligands. These compounds that can 
be modified by drug design make NR interesting drug targets. Thus, NRs 
have drawn great interest as potential drug targets in therapies of cancer, 
cardiometabolic diseases as well as disorders in central nervous system [11,12]. 
1.2.2 Structures
The ERs share considerable structural homology with other NRs [13]. The ERs are 
comprised of six distinct functional domains labeled A/B, C, D, E and F (Fig 1). 
The amino-terminal A/B domain contains activation function AF-1. The C 
domain is called DNA binding domain (DBD) and mediates sequence specific 
DNA binding activity. The DBD of ER is well conserved and displays the highest 
degree of sequence similar to other NRs. The DBD contains two domains, a 
D-box and a P-box where the “P box” is responsible for specific interaction with 
DNA on the typical estrogen response element (ERE) containing AGGTCA 
motifs, whereas the ‘D box’ is serves as a dimerization interface [14]. The 
D domain works as a flexible hinge between the C and E domain and also 
includes a nuclear localization signal. The E domain, which is also referred as the 
ligand-binding domain (LBD), contains the second activation function AF-2. The 
LBD binds to the ligand and transmits the signal to the transcription complex; it 
is also involved in receptor dimerization. AFs function as the binding sites for 
other regulatory proteins such as co-factors [15,16]; Synergistic effects between 
                 Figure 1. Schematic structural representation of the human ER.
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ER AF1 and AF2 on estrogen-induced transcription mediated by certain 
co-factors have been reported [17]. The function of the C-terminal F domain is 
not yet fully understood. 
1.2.3 Ligands
There are three endogenous estrogens, namely estrone (E1), estradiol (E2), and 
estriol (E3) (Fig 2A). As the predominant estrogen form in premenopause fe-
males, estradiol is the most potent estrogen produced in the body and both ER 
isoforms bind estradiol with high affinity; estrone and estriol are weaker agonists 
on ERs [18] and are the primary estrogens during menopause and pregnancy, 
respectively. The biological role of these compounds is however currently unclear. 
The developing follicles and ovaries are the principle source of estrogen; 
however, many other tissues and cells have also shown the capacity to synthesize 
estrogens. Importantly, in postmenopausal women and men, estrogen 
could be produced in a number of extragonadal sites such as liver, breast and 
adipose tissue [2,3,19].
Figure 2. Structures of ER ligands. (A) The three endogenous estrogens: 
estradiol, estrone and estriol. (B) Exogenous compounds that bind to ER and 
mimic the effect of estrogen: endocrine-disrupting chemicals such as DES and 
PCB; and dietary-derived ligands such as genestein.
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In addition, there are diverse exogenous compounds that bind to ER and mimic the 
effect of estrogen (Fig. 2B). Some of them are man made compounds, for example, 
certain endocrine-disrupting chemicals, such as diethylstilbestrol (DES), 
polychlorinated biphenyls (PCBs), alkylphenols, phthalates, and parabens, have 
been shown to have estrogenic effects and are known as xenoestrogens [20]. 
The exogenous ER ligands could also be dietary-derived, for example, a range 
of plant products, namely phytoestrogens, could induce estrogenic activities in 
mammals. The main classes of phytoestrogens include the flavonoids, lignans 
and coumestans, which are abundant in nuts, oilseeds and soy products [21].
1.2.4 Co-factors 
The AF-1 and AF-2 domains of ERs as well as other NRs mediate recruitment of a 
multitude of cellular regulatory co-factors which affect the rate of ER target gene 
transcription. As a crucial step in the process of ER transcriptional activation, 
regulations by co-factors are important for normal functions of ER. 
Thus, the activities and cellular concentrations of co-factors can have a 
great impact on ER-controlled physiological and pathological processes.
Co-activators represent a group of cellular factors that promote the transcriptional 
activity of the receptors in the presence of ligand. They bind to NRs receptors 
through Leu-Xaa-Xaa-Leu-Leu motifs (NR boxes). Co-activators consist of 
different classes of proteins, for instance, steroid receptor coactivator (SRC/P160) 
family, CREB-binding protein (CBP), coactivator-associated arginine methyl-
transferase 1 (CARM1) and so on. These proteins have diverse structures and 
facilitate the transcription through different mechanisms such as histone acetyla-
tion, histone methylation, or ubiquitination [22,23,24].
Alternatively, Co-repressors such as silencing mediator for retinoic acid and 
thyroid hormone receptor (SMRT) and nuclear receptor co-repressor (NcoR) are 
proteins that mediate a repressive effect of the receptors. Recent studies showed 
that co-repressors can be recruited by both agonist- and antagonist-bound ERs, 
however, the role of co-repressors for ER is not established as well as that of 
coactivators [25,26].
1.2.5 ER signaling
Two different modes of ER signaling mechanisms have been shown: the genomic 
action and the no-genomic action (Fig. 3).
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Figure 3. Mechanism of ER signaling. ER regulates gene expression through 
(A) ligand-activated ER binds to ERE; (B) ligand-activated ER binds a 
response element via another transcription factor (TF); (C) non-genomic mode.
The classical genomic ER signaling involves ER binding to specific DNA 
enhancer or promotor elements and thus regulation of expression of certain 
sets of genes (Fig. 3A). In the absence of ligand, ER is present in an inactive 
form associated with cellular chaperones like heat shock proteins (HSP90). 
In the presence of ligand the ER is activated and dissociate from the chaperones. 
Activated ER is phosphorylated and binds as homodimers or heterodimers to 
EREs in the promoter region of a target gene. The essential ERE sequence was 
determined to have the consensus inverted repeat 5’-GGTCAnnnTGACC-3’. 
ER-DNA interaction leads to a change of the local DNA structure and open up 
the DNA, which induces the recruitment of general transcription factors (GTFs) 
to the promoter and initiates the transcription of the target gene [27,28,29,30]. 
There is also another type of genomic ER signaling that involves indirect ER-
DNA binding (Fig. 3B). In this pathway, activated ERs regulate target gene in an 
ERE independent manner by interacting with other DNA-binding transcription 
factors. For instance, ERs have been shown to activate genes via specificity pro-
tein 1 (Sp1) binding site by interacting with the Sp1 transcription factor [31,32].
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The non-genomic ER signaling is characterized by the rapid ligand response and 
possibly mediated by membrane-associated ER (Fig. 3C). It has been suggested 
that these effects involve the activation of MAPK/ERK pathway in cytoplasm
[33,34]. However, the precise role of membrane bound ER is currently unclear.
1.3 ER subtypes
There are two identified ER subtypes. The first ER, ERα (ESR1, NR3A1), was 
cloned from MCF-7 breast cancer cell line in 1985 [35]. ERα was regarded as the 
only estrogen mediating receptor until a novel ER isoform, ERβ (ESR2, RN3A2), 
was cloned from rat prostate library in year 1996 [36]. Both ERα and ERβ are 
indispensable in mediating physiological functions of estrogens, however, they 
often exert distinct effects.  In many aspects, these two ER subtypes share large 
degree of similarities but also show significant differences [37,38,39]. 
1.3.1   Expression patterns
Although both ERα and ERβ are widely distributed throughout the body, they 
display distinct expression patterns in different tissues and cell types. ERα is 
mainly expressed in ovary (theca cells), uterus, prostate (stroma), testis (Leydig 
cells), epididymis, breast, liver, bone, skeletal muscle, wihite adipose tissue as 
well as certain regions of the brain, such as pituitary and hypothalamus; whereas 
ERβ is expressed in ovary (granulose cells), prostate (epithelium), testis, colon, 
lung, bone marrow, salivary gland as well as regions in the brain including hy-
pothalamus and cortex [40,41]. 
1.3.2   Structural homology
As mentioned above, both ER subtypes share considerable structural similarities 
with other members of the NR family of transcription factors. The DBDs of ERα 
and ERβ are highly homologous with 97% amino acid identity and both bind to 
the consensus ERE.  The LBDs of two ERs share relatively high degree of homol-
ogy with 56% amino acid identity, which provide a basis for binding of common 
and subtype-specific ligands. The N-terminal A/B domain is poorly conserved 
between the two ER subtypes, which display only about 20% homology. This 
counts for the different AF-1 activities and co-factor recruitment of ERα and ERβ 
[42,43].
1.3.3   Knockout animals
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Through the generation of the ER knockout (ERKO) animal models there is direct 
evidence showing the physiological roles of estrogen signaling in both reproduc-
tive and non-reproductive systems. Phenotypes of ERα and ERβ KO (αERKO 
and βERKO) mice have further illustrated both the similarities and differences of 
these two ER subtypes in biological function. 
Reproductive malfunctions are observed following disruption of either ERα or 
ERβ. In αERKO mice, both males and females are infertile, whereas in ERβ KO 
animals, only the female display subfertility. It has been suggested that both ERs 
are required for efficient ovulation, whereas ERα appears to be more critical than 
ERβ in maintenance of testicular structures and the somatic cell function required 
for successful sperm maturation [44,45]. 
It has been shown that the pubertal growth of the epithelial ductal rudiment of 
mammary gland is impaired in the αERKO female, which is due to the abnormal 
function of αERKO pituitary; in contrast, adult βERKO females display a fully 
developed mammary gland with ductal network similar to the wild type, suggesting 
that ERα, but not ERβ, is required for the structural and functional development 
of the mammary gland [44]. Moreover, higher fasting blood glucose levels and 
impaired glucose tolerance were observed in αERKO but not in βERKO mice, 
implying a more important role of ERα in mediating the estrogen effects on 
glucose metabolism [46].
The observed phenotypes of βERKO mice reveal crucial roles of ERβ in 
development and function of central nerve system (CNS), bone, hearing as well as 
respiratory system. For instance, at the late embryo stage, the brains of βERKO 
mice are smaller than those of littermate controls, especially in the cerebral cortex, 
suggesting that ERβ is a key player in brain morphogenesis [47]. It has also been 
shown that βERKO mice were deaf at 1 year of age with abnormal inner ear 
morphology such as the absence of hair cells [48]. Furthermore, there is study 
showing that βERKO mice have systemic hypoxia caused by abnormal lung 
structures including larger alveoli and reduced elastic recoil [49].
1.3.4 Ligand affinities
E2 binds the two ER subtypes with similar affinity; however, other ligands or 
compounds may differ considerably in their binding affinities for ERα and ERβ. 
For instance, E1 has been shown to display higher affinity for ERα, whereas E3 
binds preferentially with ERβ [50]. The functional consequence of this difference
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is currently unclear.
Phytoestrogens and xenoestrogens show different degree of affinities for ERα 
and ERβ [40]. For example, genistein, a soy isoflavone, manifests a much higher 
affinity for ERβ than for ERα [51], whereas another well-known phytoestrogen, 
raloxifene, displays an ERα-selective affinity [52].  It has also been reported that 
the endocrine disrupting chemicals HO-PCBs show greater binding preference
for ERβ over ERα [53]. 
Two synthetic non-steroidal compounds, propylpyrazoletriol (PPT) [54] and 
diarylpropionitrile (DPN) [55] have been identified and characterized as selective 
agonists for ERα and ERβ, respectively. PPT is approximately 1000-fold more 
potent as an ERα agonist compared to ERβ and has a 400-fold preference 
towards ERα in its binding affinity, whereas DPN shows a 70-fold higher relative 
binding affinity for ERβ than for ERα [56].
The selective estrogen receptor modulators (SERMs) refer to a group of synthetic
molecules that have estrogen-like effect in some circumstances but act as anti-es-
trogens in the others, depend on the target tissues or ER-subtype. Certain SERMs 
have shown great pharmaceutical value since they could activate the benefit effect
of ERα/β, but inhibit the undesired side effect of ERα/β. Tamoxifen was the first 
SERM that has been used in the clinical treatment [57]. Given that it displays 
an antagonistic effect on the breast while functioning as an agonist in uterus and 
skeletal tissue, tamoxifen is now widely used in breast cancer therapy.
1.3.5 Co-factor selectivity
As other NRs, activation of ER signaling requires interactions between ER with 
different co-factors. Besides the ligand-specific and tissue-specific regulation 
of ER-co-factor interaction, ERα and ERβ also show affinity preferences for 
particular co-activators. For instance, classical p160 co-activators, especially 
SRC3, bind ERα with much higher affinity [58]; on the other hand, the novel ER 
co-factor arylhydrocarbon receptor (AhR) nuclear translocator (ARNT), although 
has been identified to co-activate both ER subtypes, preferentially facilitates the 
transcriptional activity of ERβ [59].
Given that AF-1 domain serves as the binding surface for various co-factors, the 
poor sequence homology between ERα and ERβ in the AF-1domain could be 
responsible for the differential affinity preferences of co-factors for either ERα 
or ERβ. Furthermore, it’s also been shown that ERα and ERβ utilize different
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LXXLL motifs for their interaction with p160 proteins [58].
It is also noteworthy that the ER subtype-selective co-activating could have 
significant physiological importance. For example, SRC-3 amplification has been 
found in ERα-positive breast cancers [60,61], whereas AhR-ARNT ligand dioxin 
shows more potent effect in disruption of ERβ signaling [59].
1.3.6   Roles in human diseases
Different disease patterns have been noticed in male and female, as well as in 
premenopausal and postmenopausal females, implying the involvement of 
estrogen signaling in human diseases. To date, identified estrogen influenced 
diseases include cardiovascular diseases, metabolic syndrome, tumors, 
osteoporosis, neurodegenerative diseases, mode disorders, autoimmune diseases 
and so on [62,63]. 
ERα and ERβ exert opposing effects in certain diseases. For example, several 
studies have demonstrated that ERα primarily mediates the tumorigenic effects 
of estrogens. Lifetime exposure to estrogen ligands and high estrogen levels and 
thus high ER transcriptional activity represent a risk factor for developing tumors 
in breast [6], endometrial [64], ovarian [65] pituitary [66] and thyroid tissues [7]. 
In contrast, ERβ has been shown to possess a tumor suppressive effect in tissues 
such as the prostate [67] and colon [68].
1.3.7   Regulation of ER-subtype activity
Estrogen signaling is regulated by a complex multi-level procedure involving 
diverse factors. ER could display distinct activities and functions in different 
cellular environments (Fig. 4).  
Tissue-specific distribution of ER implies that regulatory factors, which influence 
the expression of ER, could act as key modulators of ER activity and estrogen 
signaling (Fig. 4A). This regulation could occur at different levels, including 
DNA modification, transcription, post-transcription and translation. However, the 
transcription regulation that controls the initiation of the ER gene transcription is 
often the principal step.
Ligand binding is the first essential regulatory step in the ER activation process 
(Fig. 4B). Different ligands induce distinct conformational changes in ER [69]. 
The structure, concentration and affinity of the ligands all have been shown to
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Figure 4. Regulation of ER activity is a multi-level procedure involving diverse 
factors such as: (A) cellular factors that influence the expression of ER; (B) 
ligand binding; (C) cellular factors that affect the accessibility of the target gene 
promoter; (D) the expression and activity of co-factors; (E) other factors and 
mechanisms.
have great influence on ER transcriptional efficiency.
Furthermore, as a transcription factor (TF), ER exhibits transcriptional activ-
ity by binding to the target gene promoter. Thus, cellular factors that affect the 
accessibility of the target gene promoter could also have significant impact on 
ER-mediated biological activities (Fig. 4C). 
In addition, the expression and activity of co-factors (Fig. 4D) as well as other 
ER associated proteins such as Sp1 could also be important determinants of ER-
mediated transcription through different mechanisms (Fig. 4E). 
1.3.8   ERα / ERβ balance
As mentioned above, ERα and ERβ have distinct functions and modulate differ-
ent effects. Actually, the two ER subtypes are often antagonistic towards each 
other. Biological action of estrogen is the result of a balance between ERα and 
ERβ mediated estrogen signaling; disruption of the ERα/ERβ balance could lead 
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to various health disorders [18,70].
The opposing roles of the two ER subtypes in regulation of cell proliferation 
have been observed. ERα has been shown to promote the cell proliferation in 
various tissues including breast, uterus as well as developing prostate; whereas 
the role of ERβ in these tissues is rather to inhibit proliferation and induce 
differentiation. This provides an important message for tumor biology since 
cell hyper-proliferation is a crucial process in tumorigenesis. Possibly an 
important role of ERβ is to protect against ERα-induced cell proliferation. 
Actually, an increased ERα/ERβ mRNA ratio in estrogen-induced tumorogenesis 
has been reported in breast, ovary, colon, and prostate cancers [71,72]. 
The relationship between ERα and ERβ are often mentioned as an “yin/yang
balance”, which describes the fact that two ER subtypes have both overlapped and 
differential functions, cooperate with each other whereas at the same time restrain 
against each other. This concept could bring a new insight for both therapy method 
and drug development in estrogen-associated diseases.
1.4 Circadian system
Circadian rhythm is an internal biological clock existing in almost all living 
organisms. It integrates and regulates a variety of biological processes according 
to a roughly-24-hour period [73]. In mammals, including humans, normal 
daily rhythm is important in maintaining physiological functions like the sleep-
wake cycle, body temperature, feeding behavior, glucose homeostasis, drug and 
xenobiotic metabolism [74]. Disruption of the normal circadian rhythm (e.g. 
shift work) is associated with health disorders such as cancer, mood disorders, 
metabolic syndrome, cardiovascular diseases, and gastrointestinal disease as well 
as reproductive malfunctions [75,76].  
1.4.1   The central and peripheral clocks 
The central circadian pacemaker in mammals is located in the suprachiasmatic 
nuclei (SCN) of the ventral hypothalamus [77]. This “master” internal clock is 
synchronized primarily by the daily light-dark cycle and coordinates the rhythms 
of multiple local clocks in peripheral tissues and cells through both neuronal and 
hormonal signals [74,78].  Lesions in the SCN region result in a loss of circadian 
rhythmicity in both behavior and hormone secretion [79,80]. 
On the other hand, although the peripheral clocks require the inputs from the 
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master clock in order to sustain the synchrony, these clocks are also adjusted 
by non-photic time cues including feeding time, hormones, growth factors and 
metabolites such as glucose [81]. It has been shown that most of the circadian 
controlled genes (CCGs) are expressed in a tissue-specific manner, demonstrating 
the importance of the local clock in regulation of tissue-specific biological 
functions [82,83]. Moreover, circadian rhythms have been identified even in 
cultured cells, which can be synchronized by treatment of high concentration of 
serum, hormones or growth factors [84,85].
1.4.2   Circadian genes 
The circadian system is regulated by a set of clock genes that highly conserved 
through evolution. Disruption of clock gene expression by mutation or KO could 
results in profound disturbance of the normal circadian rhythmicity.
The positive circadian regulators include the circadian locomotor output cycles 
kaput (CLOCK) and the brain and muscle ARNT-like protein1 (BMAL1). Both 
CLOCK and BMAL belong to the helix-loop-heix (bHLH)-PER-ARNT-SIM 
(PAS) superfamily. It has been reported that CLOCK mutant mouse heterozygotes 
displayed an abnormally long period of daily activity; and homozygotes generate 
arrhythmicity after several days in constant darkness [86].  BMAL1 is also known 
as ANRT3 or MOP3, BMAL1 KO mice lost all circadian rhythmicity in constant 
darkness and showed impaired locomotor activities (whole body movement) in 
light-dark cycles [87].
There are also negative regulators of circadian system, namely Period (PER) and 
Cryptochrome (CRY). PERs (PER1 and PER2) are also members of PAS family, 
mutations in PER2 gene has been identified in patients suffering from familial 
advanced sleep phase syndrome (FASPS) [88]. CRYs (CRY1 and CRY2) 
represent a class of blue light-sensitive flavoproteins. Interestingly, in constant 
darkness, CRY1 mutant mice display a shortened circadian period, whereas CRY2 
mutant mice had a prolonged circadian period, only double-mutant mice showed 
instantaneous arrhythmicity [89]. 
1.4.3   Molecular oscillators
Molecular circadian oscillator is driven by a transcription/translation feedback 
loop that leads to recurrent rhythms in the RNA and protein levels of key clock 
components [90] (Fig. 5)
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Figure 5. Molecular circadian oscillator is driven by a transcription/translation feed-
back loop.
The positive arm of the rhythmicity consists of CLOCK and BMAL1, which 
form heterodimer and bind to the E-box motifs within the promoter regions of 
CCGs and generate the transcription of these genes. Among these CCGs, there are 
negative circadian regulators PER and CRY. Accumulated PER and CRY proteins 
form in turn negative regulatory complexes by binding with each other as well 
as casein kinase CKIε. PER-CRY-CKIε is then phosphorylated and translocates 
to the nucleus. By interacting with the CLOCK-BMAL1, the negative regulators 
inhibit transcriptions of their own genes and other CCGs [77,81,91] and complete 
the negative arm of the loop. Furthermore, it has been shown that CLOCK has 
enzymatic histone acetyl-transferase activity could directly control the chromatin 
remodeling of target gene [92].
In addition, besides the main feedback loop, there is also another feedback loop 
known as “the second feedback loop” or “REV/ROR/BMAL1 loop”, which 
involves the orphan NRs retinoid-related orphan receptors (RORs) and REV-
ERB (α and β).  The expression of REV-ERB is regulated by CLOCK-BMAL1. 
Both ROR and REV-ERB bind to the specific response elements RORE in the 
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promoter region of BMAL1 gene and display opposite effects: ROR activates the 
transcription, whereas REV-ERB represses the transcription. Thus, the rhythmic 
expression of BMAL1 is the result of competition between REV-ERBs and RORs 
at ROREs. This mechanism contributes possibly to the robustness of the circadian 
oscillations [93].
1.4.4   Circadian clock and reproduction
Accumulating evidences suggest a clear connection between circadian rhythm 
and reproduction. The circadian system regulates the reproductive functions by 
influencing the timing of puberty, sex hormone secretion, ovulation and mating 
activities. It has been shown that CLOCK mutant female mice displayed 
malfunctions in reproductive system such as irregular estrous cycles, lack a 
coordinated luteinizing hormone (LH) surge on the day of proestrus, exhibit 
increased fetal reabsorption during pregnancy, and have a high rate of full-term 
pregnancy failure [94]. Moreover, infertility has been observed in both male and 
female BMAL1 KO mice by several labs [95,96]. In humans, despite the fact that 
only few studies have been performed, there is evidence showing associations 
between female shift workers and reproductive malfunctions such as irregular 
menstruation, increased risk of spontaneous abortion and preterm birth [97,75].
1.4.5   Circadian clock and NRs
The crosstalk between the circadian clock and the NR signaling pathway exists 
at multiple levels. First, NRs like ROR and REV-ERB could function as core 
players in the molecular pacemaker (as described above); Second, It has been 
known for decades that plasma levels of NR ligands such as glucocorticoids and 
aldosterone display daily rhythms; in addition, the expressions of several NRs 
have been identified to be clock-regulated and display a circadian pattern. These 
NRs include REV-ERB, estrogen-related receptor α (ERRα), PPARα and TRα. 
Furthermore, clinical observations imply an interaction between circadian system 
and ERs, for example, disturbance of circadian genes have been shown in breast 
cancer and a correlated decrease of PER1 and ERβ in colorectal tumors is also 
been reported [98,99]. However, although it has long been known that circadian 
clock could influence variety of physiological processes, the exact mechanism 
behind the regulation is not clear yet. One possible mechanism could be that 
circadian clock modulates physiological pathways by regulating the expression 
of certain CCGs, which are key factors in these pathways. NRs could be such 
factors that transmit the circadian rhythm from the core oscillator to 
physiological outputs [100].
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1.5 XAP2
The Hepatitis B virus X protein-associated protein 2 (XAP2), also known as 
aryl hydrocarbon receptor-associated protein 9 (ARA9) or aryl hydrocarbon 
receptor-interacting protein (AIP), is a 37 kD Hsp90-associated protein that 
belongs to the immunophilin family of proteins. XAP2 was initially identified as 
a specific AhR co-chaperone however later studies have shown that other signal 
transduction proteins are regulated by XAP2. Although XAP2 is ubiquitously 
expressed, the expression levels of XAP2 vary considerably in different tissues,
with highest levels of expression in the spleen and thymus and low expression 
levels in the liver, kidney and lung [101,102,103]. XAP2 shares structural 
homology with other immunophilins, the protein contains a peptidyl-prolyl 
cistrans isomerases (PPlase)-like domain and three tetratricopeptide repeats 
(TPR). Each of the three TPR motifs of XAP2 consists of two α-helices forming 
an antiparallel amphipathic structure that mediate intra- and inter-molecular 
interactions with other proteins, such as Hsp90 [104]. 
1.5.1   Traditional functions of XAP2
Although structurally sharing a significant homology with immunophillins, 
XAP2 does not function as other immunophinlins to mediate the effects of 
immunoreppressant drugs [104]. It was originally identified as a negative regulator 
of the hepatitis B virus X-associated protein [103]. Later, the role of XAP2 as 
an Hsp90-associated protein in regulating AhR was intensively studied. It has 
been shown that low levels of XAP2 expression enhanced human AhR signaling, 
whereas high-level expression of XAP2 blocked AhR signaling in a synthetic 
yeast model system [105]. In mammalian cells, XAP2 interacts specifically 
with AhR-Hsp90 complex and induces the cytoplasmatic redistribution 
of AhR [103,106]. In addition, XAP2 stabilizes the AhR in the absence of ligand 
by inhibiting AhR ubiquitination and proteosomal degradation [107]. 
1.5.2   Novel roles of XAP2
The sequence of XAP2 protein is highly conserved through evolution. Moreover, 
XAP2 KO mice display cardiac defects and 100% embryonic lethality [108]. This 
evidence suggests that XAP2 could be involved in a wider range of biological 
processes. Remarkably, increasing numbers of XAP2 client regulated proteins 
with diverse physiological functions have been identified as interacting partners 
of XAP2. These proteins include not only chaperone proteins and viral proteins, 
but also novel XAP2 partners such as G proteins, transmembrane receptors, 
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mitochondrial import receptors as well as several NR family members [109].
Recently, the tumor suppressive role of XAP2 has drawn considerable interest 
in clinical studies. Germline mutations in XAP2 genes have been identified in 
both familial and sporadic pituitary tumor patients [110]. Clinical data showed 
that about 30% of all familial isolated pituitary adenoma (FIPA) families and 
50% of acromegaly families carry a mutation in the XAP2 gene [111]. Patients 
with XAP2 mutations predispose to young-onset pituitary tumours, most often to 
growth hormone-or prolactin-secreting adenomas [104]. The molecular mecha-
nisms behind the tumor suppressive-activity of XAP2 have however not been 
clarified yet. One possibility is that the XAP2 interacts with regulatory factors 
and thus modulates pathways involved in tumor development as well as other 
pathological processes. Interestingly, several studies have showed that estrogen 
could induce the formation and development of pituitary tumor [112,113], sug-
gesting the involvement of ER-regulated signaling pathways in pituitary tumor 
pathogenesis. In addition, Naves and co-workers reported precautious puberty 
in a one-year-old female XAP2 mutation carrier [109], implying a modified ER 
signaling in XAP2 mutated individuals.
1.5.3   XAP2 and NRs
Resent studies have demonstrated a physical and functional role for XAP2 in 
regulation of certain members of the NR superfamily. 
In year 2003, Sumanasekera et al. reported that XAP2 could interact with PPARα 
and repress its activity in mouse liver [114]. 
In addition, Froidevaux et al. in 2006 indentified XAP2 as a novel partner for 
TRβ1. They demonstrated TR-XAP2 interactions were TR isoform specific and 
could be enhanced by T3. They also shown that knockdown of XAP2 protein 
level by siRNA could influence the stability of TRβ1 in vitro and abrogated the 
TRβ1-mediated activation of hypothalamic TRH transcription in vivo. However, 
their experiments suggest that XAP2 doesn’t seem to affect the subcellular 
localization of TRβ1 [115].
Later, in 2009, another NR, GR, has been identified to be XAP2 asscociated. 
In mammalian cells, XAP2 has shown to interact with GR through Hsp90 and 
inhibits GR signaling by delaying the nuclear translocation of lignd-bound GR 
[116].
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1.6 DNA methylation
1.6.1   Epigenetic regulation
Epigenetic regulation refers to the heritable modifications in gene expression and 
function that occur without a change in the DNA sequence. In mammals, the 
epigenetic modifications include DNA methylation, post-translational 
modifications of histone proteins and non-coding RNAs. By determining 
the expression pattern of genes, epigenetic regulation plays crucial role 
during growth and development. Epigenetic homeostasis in cells is essential in 
maintenance of normal cellular functions [117,118]. 
1.6.2   DNA methylation
DNA methylation is the only known epigenetic modification of DNA in 
mammals [119] and is an inhibitory factor of gene expression [120]. The 
predominant form of DNA methylation is methylation of cytosine at position 
C5 in CpG dinucleotides in the target promoter, which could either inhibits 
the binding of transcriptional activating proteins or recruits methylated 
DNA-binding factors to the promoter [121]. The CpG island is a DNA 
fragment with high frequency of the CG sequence. CpG methylation could 
induce histone deacetylation, chromatin remodeling and thereby lead to a 
gene silencing [122]. In addition, importance of non-CpG methylation has 
been more and more emphasized. For instance, cytosine-5 methylation at CpA 
and CpT has shown to present significantly in embryonic stem cells [123]; 
also, 5-methylcytosine can be converted to 5-hydroxymethylcytosine by the 
ten-eleven translocation (TET) methylcytosine dioxygenases[117]. 
Furthermore, in human and other mammals, demethylation and remethylation 
occur genome-widely during the early embryonic development [124,125,126]. 
Resently, Tet-catalyzed oxidation followed by decarboxylation has been 
proposed to be a possible mechanism of the DNA demethylation [127,128].
1.6.3   DNA methylation and diseases
DNA methylation is crucial in regulating many cellular processes; defects of 
normal DNA methylation are correlated with various human diseases. In cancers, 
hypomethylation in genomes of cancer cells occurs at the very early stage of 
carcinogenesis and has shown to correlate with disease severity and metastatic 
potential [119,129,130,131]; methylation status in skeletal muscle from type 2 
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diabetes differs significantly from normal glucose-tolerant volunteers, suggesting 
a role of DNA methylation in metabolic disorders [132]; Moreover, DNA 
methylation is also associated with autoimmuno diseases such as systemic lupus 
erythematosus, it has been suggested that the genomes of T cells in these patients 
are globally hypomethylated, which result in the autoantibody response [119].
1.7 Glut4
Glucose transporters (Gluts) represent a family of proteins that responsible for the 
glucose uptake into cells by transporting glucose cross the plasma membranes. 
The Glut family consists of several isoforms (Glut1-Glut5), which are expressed 
by various cell types and play essential roles in maintaining glucose homeostasis. 
The Glut4 isoform is the insulin-response glucose transporter in skeletal muscle, 
cardiac muscle and adipose tissue [133,134]. 
1.7.1   Functions of Glut4
Glut4 functions as the major mediator of insulin-stimulated glucose uptake into 
striated muscle and adipose tissue. In the low-insulin condition, Glut4 is stored in 
intracellular pools. Experiments have shown that rise of blood glucose level (e.g. 
after food intake) will induce insulin secretion, which leads to the translocation 
of Glut4 storage vesicles to the plasma membrane. Glut4 proteins will then be 
inserted into the cell surfaces as these Glut4-containing vesicles fuse with the 
plasma membrane. Glut4 will subsequently promote import of glucose into for 
example muscle cells and subsequently a reduction in circulating glucose levels 
[134,135,136,137]. The major regulator of Glut4 function is insulin, which binds 
to the insulin receptor and induces a rapid translocation of Glut4; the number 
of Glut4 at the cell surface of muscle cells could also induced by contraction, 
depolarization, or energy deprivation [138]. In addition, other factors, such as 
estrogen, could also affect Glut4 function by regulating the expression level of 
Glut4 in different tissues [139].
Phenotypes of transgenetic animals imply an essential role of Glut4 in glucose 
metabolism.  Glut4 KO (Glut4 -/-) mice show not only severe metabolic disorders 
including impaired insulin tolerance, hyperinsulinaemia, decreased levels of 
lactate, non-esterified fatty acids, β-hydroxybutyrate as well as fat tissue 
deposition, but also other disorders such as growth-retarded and cardiac
hypertrophy; on the other hand, overexpression of Glut4 in skeletal muscle 
results in increased glucose metabolism and protects against the development of 
insulin resistance and diabetes mellitus [140,141,142].
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In addition, pretranslational suppression of Glut4 has been shown in adipocytes 
from obese and non-insulin-dependent diabetes mellitus (NIDDM) patients. It is 
also suggested the Glut4 deficiency is a major cause of cellular insulin resistance 
in these patients [143]. Furthermore, exercise training increased Glut4 expression 
in muscle is associated with enhanced glucose tolerance Therefore, to increase 
the number of Glut4 in the plasma membrane in muscle and adipocytes may be a 
novel therapeutic method in the treatment of diseases such as NIDDM [135].
1.7.2   Transcriptional regulation of Glut4 expression
The human Glut4 promoter harbors two functional regulatory domains: the Glut4 
enhancer factor (GEF) binding domain (domain I) and the myocyte enhancer 
factor 2 (MEF2) binding domain (domain II). The regulation of Glut4 expression 
is the cooperation between these two domains [144]. 
The transcription of Glut4 is under the control of variety of TFs. In muscle and 
adipose tissue, transcriptional activating factors for Glut4 expression include 
MEF2, GEF, MyoD, C/EBP-α, SREBP-1c and NR family members TRα 1 and 
LXRα; the repressor of Glut4 gene include tumor necrosis factor-α, dioxin, free 
fatty acids, nuclear factor-1 as well as NR PAPRγ[145]. In addition, Sp1 is shown 
to bind to the Glut4 promoter and facilitates the SREBP-1c mediated activation 
of Glut4 [146]. 
1.7.3   Glut4 and ER
Both ERα and ERβ have been suggested to regulate Glut4 expression levels 
[145,147]. Studies in ERα and ERβ KO mice suggest that ERβ reduces, whereas 
ERα enhances Glut4 protein levels in muscle and white adipose tissue [147]. This 
observation is strengthened by the fact that ERα, but not ERβ knockout mice 
show impaired glucose and insulin tolerance [8]. However, opposite effects have 
been shown in a hamster ovary cell line, where the selective activation of ERβ 
induces Glut4 expression [148]. Moreover, it has also been reported that ERβ 
inhibits the activity of PPARγ [149], one of the repressors of Glut4 transcription. 
Taken together, the roles of ERs on Glut4 activity are so far contradictory. It is 
possible that the ER subtype-dependent regulation of Glut4 is tissue- and cell 
type-specific. 
1.7.4   DNA methylation and Glut4 expression
Previous experiments have shown that expression of Glut4 is also regulated 
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at the epigenetic level; for example, CpG methylation plays an important 
regulatory role in adipogenesis and glucose homeostasis. Tissue-specific level 
of methylation is an important determinant for the tissue-specific expression 
of metabolic regulation factors [150,151]. The transcription of Glut4, for 
example, is regulated by methylation. Studies show that demethylation on 
Glut4 promoter occurs during the differentiation of preadipocyte to adipocytes, 
methylations at certain CpG sites prevent the activation of Glut4 promoter 
[152]. Thus, DNA methylation may play as a mediator between environmental 
factors and metabolic disorders such as diabetes [132,153]. However, further 
studies are required to fully understand the mechanism clinical meaning of the 
methylation-dependent gene regulation.
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2 AIMS OF THESIS
The general aim of the thesis is to characterize possible mechanisms by which 
the estrogen signaling could be regulated in an ER subtype-specific manner. In 
particular, our studies aimed at:
  •  Investigate the circadian impact on the expression of ER subtypes and 
         consequent effects on estrogen signaling (paper I).
       •      Characterize the role of XAP2 on ERα- and ERβ-mediated estrogen signaling 
        (paper II).
    •    Compare the effects of ERα and ERβ on Glut4 activity and characterize the 
         mechanisms behind the effects (paper III).
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3 RESULTS AND DISCUSSION
3.1 Paper I: EXPRESSION LEVELS OF ESTROGEN RECEPTOR β ARE 
      MODULATED BY COMPONENTS OF THE MOLECULAR CLOCK
Overlap between circadian-regulated and ER-related physiological disorders 
have been observed in both reproductive and non-reproductive tissues, suggest-
ing a link between these two transcription pathways. In this study performed 
in collaboration with Vincent Laudet (Ecole Normale Supérieure de Lyon) and 
Franck Delaunay (Université de Nice-Sophia-Antipolis), we identify a novel 
regulatory level of estrogen signaling where ER is controlled by the circadian 
clock. Remarkably, our experiments indicate that only one ER subtype, ERβ, is 
regulated by components of the molecular clock, whereas ERα is not under the 
circadian regulation.
By using Real-time PCR, we show that ERβ mRNA oscillates in WT mice lung 
and muscle, with a robust circadian pattern with a peak at zeitgeber time (ZT) 12. 
This oscillatory pattern is maintained under free-running conditions and abolished 
in clock deficient BMAL1 KO mice. However, there was no oscillation in ERα 
expression in either WT or BMAL1 KO mice tissues. 
To investigate whether ERβ is under the direct regulation of the molecular 
circadian components, we performed transient transfection and chromatin 
immunoprecipitation (ChIP) experiments. Results from these experimetns 
indicated that CLOCK-BMAL1 heterodimers are efficiently recruited to a 
conserved E-box enhancer element in the ERβ promoter and mediate 
transcriptional activation. In addition, we showed that the repressive circadian 
factors PER-CRY are recruited to inhibit transcription. To identify which of the 
positive or the  negative components of the circadian cycle are the critical 
components regulating ERβ expression, we performed siRNA assays and 
demonstrate that CLOCK or PER1 knock down leads to elevated expression of 
ERβ. This result suggests that ERβ circadian cycling is primarily maintained 
through PER1 recruitment to the ERβ promoter and that CLOCK-BMAL1 serve 
as a docking point for PER1 (Fig. 6). 
Furthermore, using HC11 cells with stably transfected 3xERE reporter, we 
show that the expression levels of the circadian regulatory factors directly and 
specifically influence ERβ-mediated estrogen signaling by regulating the 
intracellular levels of endogenous ERβ. 
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Figure 6. CLOCK:BMAL1 heterodimer mediates the circadian regulation of ERβ 
by binding to the E-box enhancer in ERβ promoter, but the negative regulators 
work as the main driver of the rhythmic expression of ERβ. 
(A) In WT mice and cells, recruitment of negative circadian regulator PER:CRY 
causes an inhibition of ERβ expression, and the release of PER:CRY results 
in an up-regulation of ERβ expression induced by CLOCK:BMAL1 and other 
unknown activating transcription factors. 
(B) In BMAL1 KO mice or CLOCK deficient cells, where CLOCK:BMAL1 
heterodimer is not formed, the negative regulators are not recruited to the E-box 
enhancer and the expression of ERβ is induced by unknown activating transcription 
factors (X) and kept at a constant high level.
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3.2 Paper II: THE IMMUNOPHILIN-LIKE XAP2 IS A NEGATIVE 
  REGULATOR OF ESTROGEN SIGNALING THROUGH 
       INTERACTION WITH ESTROGEN RECEPTOR α
Previous studies have demonstrated that XAP2 mutations are associated with 
pituitary tumors. Furthermore, there is an over-representation of reproductive 
tumors among patients with non-functional XAP2 expression, suggesting a 
possible role of XAP2 in regulating estrogen signaling in connection with tumor 
development. In this study, in collaboration with Marta Korbonits (Queen Mary 
University of London) we show that XAP2 regulates estrogen signaling in an ER 
subtype-specific manner, by inhibiting ERα but not ERβ-mediated transcription. 
At the beginning of the study, we demonstrate that XAP2 has a negative on 
expression of the breast cancer marker gene pS2 as well as another ER target 
gene GREB1 in MCF-7 cells, suggesting a regulatory role of XAP2 in estrogen 
signaling. Interestingly, siRNA assays showed that knockdown of XAP2 led to 
an increase of 3xERE expression in only PPT and E2 treated cells, but not DPN 
treated cells. This result suggests that XAP2 downregulates ERα but not ERβ-
mediated estrogen signaling.
Then we proceeded further to investigate the mechanism behind the XAP2-ER 
regulation. Although XAP2 has previously been shown to protect AhR from 
protein degradation by inhibiting AhR ubiquitination, reduction of XAP2 
protein did not affect the intracellular protein levels of ERα. However, both our 
in vivo and in vitro experiments indicate that XAP2 interacts with ERα. Using 
mutated forms of XAP2 protein we demonstrated that mutations that disrupt 
XAP2-ERα interaction could no longer regulate ERα-mediated gene transcription, 
suggesting that XAP2-ERα interaction is crucial for XAP2 to inhibit 
ERα-mediated transcription; in addition, these experiments also provide 
evidence that the C-terminus of XAP2 protein (i.e. 2nd and 3rd TPR domains) 
seems to be important for mediating the XAP2-ERα protein-protein interactions. 
To monitor the possible presence of XAP2 on the regulatory promoter regions 
of ERα target genes, we performed sequential chromatinimmunoprecipitation 
(Re-ChIP) assays. Results showed that XAP2 is recruited, or already present on 
ER-regulated promoters, together with ERα; addition of the ligand led to a lower 
recruitment of the ERα/XAP2 complex. Furthermore, we observed that depletion 
of XAP2 with siRNA led to an increased recruitment of ERα to ER-target gene 
promoters (Fig. 7).  
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Figure 7. Schematic model of XAP2 regulation of ER-dependent transcription.
(A) Upon the ligand (black diamond) binding, ERα is activated, WT XAP2 is 
starting to be released from the promoter whereas more ERα is recruited to the 
promoter and the target gene transcription is initiated. 
(B) When XAP2 is mutated or knocked down, there is less or no functional 
XAP2 that could interact with ERα, ERα is recruited more actively to the target 
gene promoter and the transcription is highly induced.
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3.3 Paper III: EPIGENETIC REGULATION OF GLUCOSE 
      TRANSPORTER 4 BY ESTROGEN RECEPTOR β
Glut4 is an important regulator of cellular glucose uptake in adipose tissue and 
skeletal muscle. It has been shown that Glut4 activity could be modulated by 
ERs. However, the regulatory mechanisms behind this regulation remain unclear. 
In this study, we compared the roles of ERα and ERβ in Glut4 regulation and 
investigated the mechanism behind the regulation.
To investigate how the lack of either ER subtype affects Glut4 expression, mouse 
embryonic fibroblasts (MEFs) derived from WT, ERKO and βERKO mice were 
used. Given that Glut4 expression is restricted to skeletal muscle, heart, and 
adipose tissue in mice, MEFs from WT, ERKO and βERKO mice were 
differentiated into adipocytes in order to induce Glut4 expression. Comparison 
of Glut4 expressions between the ER proficient and deficient cells showed that 
Glut4 transcription was markedly reduced in βERKO MEF-derived adipocytes 
than in WT, both basally and upon induction by liver X receptor. Interestingly, 
there was no significant difference of Glut4 transcriptional levels in ERKO and 
WT MEF-derived adipocytes. These results suggest that ER regulates Glut4 
expression in an ER subtype dependent manner, with only ERβ but not ERα 
affecting Glut4 transcription. 
These changes in Glut4 expression however could not be explained by the lack 
of ERβ as ligand-activated transcription factor since Glut4 expression was not 
significantly modulated by E2 or re-introduction of ERβ. Given that Glut4 
expression may be regulated by DNA methylation, we investigated if there are 
changes in DNA methylation of the Glut4 promoter between ERβ proficient and 
deficient cells. Methylation levels of the two CpG islands of Glut4 promoter 
were assessed by pyrosequencing of bisulfite converted DNA from the MEFs and 
hypermethylation of one specific CpG in island 1 (CpG11) was observed in the 
ERβ deficient cells. In addition, re-introduction of ERβ into ERβ deficient cells 
partly restored Glut4 transcription and stabilised low DNA methylation after 
treatment with the DNA demethylating agent 5-Aza-2’-deoxycytidine, suggesting 
that the presence of ERβ prevents Glut4 silencing by impeding the methylation 
of CpG11.
In silico analysis of the Glut4 promoter region revealed CpG11 is part of an Sp1 
binding site. Our ChIP assays confirmed the binding of Sp1 to CpG island 1 in WT 
and ERKO MEFs. However, this binding was substantially impaired in βERKO 
MEFs due to the hypermethylation of CpG11. Treatment with Sp1 inhibitor
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diminished Glut4 expression in WT, but not in ERβ deficient cells, suggesting 
that reduced recruitment of Sp1 to the Glut4 promoter is responsible for the 
differences in Glut4 expression. 
ChIP assays showed that ERβ is the only ER subtype that is recruited to the 
CpG11 containing region of Glut4 promoter. Although ER has previously been 
shown to activate genes via Sp1 binding sites by ligand-dependent binding to 
Sp1, our electrophoretic mobility shift assay (EMSA) experiments suggest that 
the binding of Sp1 to Glut4 promoter is ERβ-independent and ERβ seems to bind 
to a region adjacent to the Sp1 site (Fig 8). 
Figure 8. Model for ERβ action on the Glut4 promoter. 
In WT and ERKO cells, ERβ prevents methylation of CpG11 that is part of an 
Sp1 binding site. In adipocytes derived from these cells, Sp1 can bind to the 
Glut4 promoter and activate basal transcription and inducibility by liver X 
receptor (LXR). In βERKO cells, on the other hand, CpG11 is methylated, which 
prevents Sp1 from binding to its recognition site and thus both basal and inducible 
Glut4 transcription are reduced. RXR: retinoid X receptor, the heterodimerisation 
partner of LXR.
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4 DISCUSSIONS
The balance of ERα/ERβ activity is crucial in keeping normal physiological 
functions of estrogen. The differential effects of ERα- and ERβ-mediated 
estrogen action are key factors in tissue-specific response of estrogen and tightly 
regulated by various factors at multiple levels. The aim of this thesis is to 
characterize possible mechanisms and pathways by which the ER activity could 
be regulated in an ER subtype-specific manner. 
Local protein levels of ERα and ERβ as well as ERα/ERβ ratio are important 
determinants for estrogen action. In paper I we demonstrate that circadian 
system could regulate estrogen signaling by specifically modulating the 
expression of ERβ. We show an example of TFs affecting intracellular levels of 
ER by direct regulation of ER transcription. Being controlled by different ranges 
of TFs, ERα and ERβ display distinct expression patterns in the body. Interestingly 
our studies show that ERα/ERβ ratio not only differs among different tissues 
and cell-types, but also varies significantly at different times of the day. In this 
case, in ERβ dominant tissues, estrogen responses might fluctuate between 
day and night whereas estrogen actions in ERα dominant tissues would show 
little or no diurnal variation. In tissues where both ERs are present at 
comparable levels, the effect of estrogen might also differ from the day to the night 
due to the fluctuated ERα/ERβ ratio. Daytime-dependent oscillations in estrogen 
action could lead to changes in susceptibility of ER-related diseases. Further-
more, this suggests that drug delivery time schedule in estrogen therapy need to 
be taken into account to optimize efficacy and avoid the side effect of the treat-
ment. 
Cellular factors could affect the transcription also by regulating TFs on the target 
gene promoter. In paper II, we show that XAP2 influences ERα-mediated estrogen 
signaling by interacting with ERα on the promoter region of ER-target gene in 
breast cancer cells. Through this mechanism, XAP2 regulates the transcriptional 
response to estrogen in an ER subtype-specific manner, as XAP2 inhibits ERα, 
but not ERβ-mediated transcription. XAP2 has been suggested to have tumor 
suppressive function, however, the detailed mechanism is not yet clear. One 
possibility is that XAP2 interacts with critical proteins in tumorigenesis-related 
transcriptional signaling pathways. Given the important roles in tumor 
development, ERs and other NRs could be the candidate regulatory factors that 
connect XAP2 with biological outcomes. Given that the effect of XAP2 on 
estrogen signaling is ER subtype dependent, the disturbance of XAP2 expression, 
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for instance, in individuals carrying XAP2 gene mutants, would break the 
normal balance between ERα and ERβ actions by over-activating ERα mediated 
estrogen signaling pathway. As a consequence, these individuals could have higher 
risk of developing estrogen related tumors since only the “proliferation promoter” 
ERα, but not the “proliferation inhibitor” ERβ is stimulated. This finding 
suggests a possible mechanism involved in the tumor suppressor function of XAP2. 
However, further investigations, especially clinical studies, are necessary to 
substantiate the suppressive role of XAP2 on tumor development.
In paper III we identify a novel epigenetic mechanism under the ER subtype-
specific regulation of gene expression. We show that ERβ, but not ERα, is essential 
in maintaining the unmethylated state of CpG11 in Sp1 binding site of Glut4 
promoter, which is required for normal Sp1 recruitment and Glut4 transcription 
in adipocytes. ERβ but not ERα is highly expressed after egg fertilization when 
global demethylation and remethylation, suggesting that ERβ is the only ER 
subtype involved in establishing the methylation pattern of genes such as Glut4. 
Furthermore, exposure to endocrine disruptive chemicals such as bisphenol A 
or diethylstilbestrol during sensitive developmental stages is known to “prime” 
the exposed organism to different metabolic disorders such as obesity and 
diabetes type 2. This is possibly due to the disturbance of normal ER activities 
since ERs are important regulators in fat and glucose metabolism. Therefore, the 
mechanism revealed in this paper provides a possible link between changes in 
glucose tolerance and epigenetic alterations observed after exposure to endocrine 
disruptive chemicals in early development. However, the ER regulation of Glut4 
seems to be complex and might involve different mechanisms and pathways, 
further investigations are required to elucidate the whole picture of the regula-
tion. 
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5 CONCLUSIONS
ER subtype specific activities are involved in many physiological and 
pathological processes. Understanding the mechanisms of ER subtype specific 
regulation is important in studying the estrogen signaling. In this thesis, we show 
how the activities of ERα and ERβ being modulated by various cellular factors 
at different levels. We have identified three novel pathways in mediating the ER 
subtype specific regulatory effects, which are summarized and presented in Fig 9. 
Figure 9. The three pathways of mediating the ER subtype specific regulatory 
effects presented in this thesis. (A) The expression of ERβ is regulated by 
components of the molecular clock (paper I); (B) XAP2 inhibits ERα-mediated 
estrogen signaling (paper II); (C) Epigenetic regulation of Glut4 by ERβ (paper 
III).
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6 FUTURE PERSPECTIVES
The meticulous and thorough regulation of ERα and ERβ activation is essential 
in maintaining the normal biological function of estrogens. This regulatory 
process involves the crosstalk of various mechanisms and pathways. There-
fore, getting a systematic view of the regulation is important. In this case, high 
throughput screening such as RNA-seq, ChIP-seq, RNAi screening as well 
as epigenome-wide association studies (EWAS) need to be applied to better 
understand the interaction network of different pathways. Furthermore, clinical 
studies, where ERα/ERβ activities are determined in patients suffering 
estrogen-related diseases, will provide valuable information for understanding 
the biological relevance of the regulation. 
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